专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010039885A3 CRYSTALLINE FORMS OF DEXLANSOPRAZOLE 审中-公开
标题翻译：结晶形式的去兰布拉唑
公开(公告)号：WO2010039885A3
公开(公告)日：2010-06-24
申请号：PCT/US2009059103
申请日：2009-09-30
申请人： TEVA PHARMA , TEVA PHARMA , RENDELL JACOB , MITTELMAN ARIEL , MOSHKOVITS-KAPTSAN RINAT , FINE SERGEI , KWOKAL ANA , KOLTAI TAMAS
发明人： RENDELL JACOB , MITTELMAN ARIEL , MOSHKOVITS-KAPTSAN RINAT , FINE SERGEI , KWOKAL ANA , KOLTAI TAMAS
IPC分类号： C07D401/12 , A61K31/44
CPC分类号： C07D401/12
摘要： Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof.
摘要翻译：提供的是dex兰索拉唑的结晶形式，以及其制备方法。

2. 发明申请

WO2009060318A3 POLYMORPHIC FORMS OF RAMELTEON AND PROCESSES FOR PREPARATION THEREOF 审中-公开
公开(公告)号：WO2009060318A3
公开(公告)日：2009-05-14
申请号：PCT/IB2008/003799
申请日：2008-07-14
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , PERLMAN, Nurit , RAFILOVICH, Michal , MOSHKOVITS-KAPTSAN, Rinat , ARONHIME, Judith , BEN MOHA-LERMAN, Elena , LIFSHITZ-LIRON, Revital , TEVA PHARMACEUTICALS USA, INC.
发明人： PERLMAN, Nurit , RAFILOVICH, Michal , MOSHKOVITS-KAPTSAN, Rinat , ARONHIME, Judith , BEN MOHA-LERMAN, Elena , LIFSHITZ-LIRON, Revital
IPC分类号： C07D307/77 , A61K31/343 , A61P25/20
摘要： An amorphous form of ramelteon is provided, as well as mixtures of amorphous and crystalline ramelteon. Also provided are methods of preparing amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, pharmaceutical compositions comprising amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, and methods of treatment of insomnia using the compositions of the invention. (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionainide, whose international nonproprietary name is ramelteon, has the following chemical structure Formula (I). Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor.

3. 发明申请

WO2009060318A2 POLYMORPHIC FORMS OF RAMELTEON AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译： RAMELTEON的多晶形式及其制备方法
公开(公告)号：WO2009060318A2
公开(公告)日：2009-05-14
申请号：PCT/IB2008003799
申请日：2008-07-14
申请人： TEVA PHARMA , TEVA PHARMA , PERLMAN NURIT , RAFILOVICH MICHAL , MOSHKOVITS-KAPTSAN RINAT , ARONHIME JUDITH , BEN MOHA-LERMAN ELENA , LIFSHITZ-LIRON REVITAL
发明人： PERLMAN NURIT , RAFILOVICH MICHAL , MOSHKOVITS-KAPTSAN RINAT , ARONHIME JUDITH , BEN MOHA-LERMAN ELENA , LIFSHITZ-LIRON REVITAL
CPC分类号： C07D307/77
摘要： An amorphous form of ramelteon is provided, as well as mixtures of amorphous and crystalline ramelteon. Also provided are methods of preparing amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, pharmaceutical compositions comprising amorphous ramelteon and mixtures of amorphous and crystalline ramelteon, and methods of treatment of insomnia using the compositions of the invention.
摘要翻译：提供了无定形形式的拉面，以及无定形和结晶拉米尔顿的混合物。还提供了制备无定形拉米尔顿的方法以及无定形和结晶拉米尔顿的混合物，包含无定形拉米尔顿的药物组合物和无定形和结晶拉米尔顿的混合物的方法，以及使用本发明的组合物治疗失眠的方法。

4. 发明申请

WO2008137134A3 AMORPHOUS ELETRIPTAN HYDROBROMIDE AND PROCESS FOR PREPARING IT AND OTHER FORMS OF ELETRIPTAN HYDROBROMIDE 审中-公开
标题翻译：非索非那曲坦碱水解物及其制备及其他形式的氯吡格雷
公开(公告)号：WO2008137134A3
公开(公告)日：2009-02-05
申请号：PCT/US2008005770
申请日：2008-05-01
申请人： PLUS CHEMICALS BV , TEVA PHARMA , MENDELOVICI MARIOARA , LANCRY ELI , MOSHKOVITS-KAPTSAN RINAT
发明人： MENDELOVICI MARIOARA , LANCRY ELI , MOSHKOVITS-KAPTSAN RINAT
IPC分类号： C07D403/06 , A61K31/404 , A61P25/06
CPC分类号： C07D403/06
摘要： The invention encompasses amorphous elelnptan hydrobromide, processes for preparing it and pharmaceutical compositions of it. The invention also relates to processes for preparing other forms of eletriptan hydrobromide such as Form a and Form ß.
摘要翻译：本发明包括无定形伊立替尼氢溴酸盐，其制备方法及其药物组合物。本发明还涉及制备其它形式的依托曲坦氢溴酸盐的方法，例如Form a和Formβ。

5. 发明申请

WO2007103221A3 AN IMPROVED PROCESS FOR THE PREPARATION OF ARMODAFINIL 审中-公开
标题翻译：改进ARMODAFINIL的制备方法
公开(公告)号：WO2007103221A3
公开(公告)日：2008-06-26
申请号：PCT/US2007005451
申请日：2007-03-01
申请人： TEVA PHARMA , TEVA PHARMA , MOSHKOVITS-KAPTSAN RINAT , BRAUDE VIVIANA , CHEN KOBI , ADLER MIRI
发明人： MOSHKOVITS-KAPTSAN RINAT , BRAUDE VIVIANA , CHEN KOBI , ADLER MIRI
IPC分类号： C07B57/00 , A61K31/192 , A61P25/00 , C07C315/06 , C07C317/44 , C07C319/24 , C07C321/20
CPC分类号： C07C315/06 , C07B57/00 , C07B2200/07 , C07C319/24 , C07C317/44 , C07C321/20
摘要： The invention encompasses processes for preparing intermediates, such as (R)-modafinic acid and its C 1-2 alkyl ester, and the conversion of the intermediates into armodafinil. In particular, the invention concerns: (i) a process for the optical resolution of modafinic acid with (R)-a-naphthylethylamine and its conversion into armodafinil; (ii) (R)-modafinic acid containing less than 2% area by HPLC of (S)-modifinic acid; (iii) a process for the preparation of C 1-2 alkyl ester of (R)-modafinic acid from (R)-modafinic acid by reaction with methanol or ethanol in the presence of at least one acidic reagent and its conversion into armodafinil; (iv) armodafinil with less than 0.5% area by HPLC of (S)-modafinil entantiomer, a pharmaceutical composition containing it and process for the preparation of this composition; (v) armodafinil with less than 0.1% area by HPLC of modafinic acid, a pharmaceutical composition containing it and process for the preparation of this composition; (vi) a process for the reduction of modafinic acid content in armodafjnil by contacting a solution with activated basic or neutral alumina; (vii) armodafinil with less than 0.2% area by HPLC of bis(diphenylmethyl) disulphide (R-MDF-DS), a pharmaceutical composition containing it and process for the preparation of this composition; (viii) a process for the preparation of R-MDF-DS from diphenylmethanethiol acetate; and (ix) a process for the reduction of R-MDF-DS content in armodafinil by suspending it in a C 5-10 hydrocarbon.
摘要翻译：本发明包括制备中间体的方法，例如（R） - 莫多卡因酸及其C 1-12烷基酯，以及中间体转化成犰狳。特别地，本发明涉及：（i）用（R）-α-萘基乙胺及其转化成犰狳的光解析莫多卡因酸的方法; （ⅱ）（S） - 二氢ic酸通过HPLC测定含有小于2％面积的（R） - 莫达卡因酸; （iii）通过与甲醇或乙醇在至少一种酸性的存在下反应制备（R） - 莫丹克酸的（R） - 莫丹克酸的C 1-12烷基酯的方法试剂及其转化成犰狳; （iv）通过HPLC（S） - 莫达非尼对映异构体的HPLC（含有它的药物组合物）具有小于0.5％面积的犰狳，以及制备该组合物的方法; （v）含有不饱和脂肪酸的药物组合物，含有它的药物组合物的面积小于0.1％的臂多糖，以及制备该组合物的方法; （vi）通过使溶液与活性碱性或中性氧化铝接触来降低犰狳中莫达非酸含量的方法; （vii）含有二（二苯基甲基）二硫化物（R-MDF-DS）的双（二苯基甲基）二硫化物（R-MDF-DS））面积小于0.2％的犰狳，含有该组合物的药物组合物及其制备方法; （viii）从二苯基甲硫醇乙酸酯制备R-MDF-DS的方法; 和（ix）通过将其悬浮在C 5-10烃中来降低含量在犰狳中的R-MDF-DS含量的方法。

6. 发明申请

WO2007103221A2 AN IMPROVED PROCESS FOR THE PREPARATION OF ARMODAFINIL 审中-公开
标题翻译：改进ARMODAFINIL的制备方法
公开(公告)号：WO2007103221A2
公开(公告)日：2007-09-13
申请号：PCT/US2007/005451
申请日：2007-03-01
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , MOSHKOVITS-KAPTSAN, Rinat , BRAUDE, Viviana , CHEN, Kobi
发明人： MOSHKOVITS-KAPTSAN, Rinat , BRAUDE, Viviana , CHEN, Kobi
IPC分类号： C07B57/00 , C07C315/06 , C07C317/44 , C07C319/24 , C07C321/20 , A61K31/192 , A61P25/00
CPC分类号： C07C315/06 , C07B57/00 , C07B2200/07 , C07C319/24 , C07C317/44 , C07C321/20
摘要： The invention encompasses processes for preparing intermediates, such as R-modafinic acid or (R)-C 1-2 alkyl ester, of modafinic acid, and the conversion of the intermediates to armodafinil.
摘要翻译：本发明包括用于制备modafinic酸的中间体如R-莫沙芬酸或（R）-C1-2-2烷基酯的方法，以及中间体转化为犰狳。

7. 发明申请

WO2011123754A1 RALTEGRAVIR SALTS AND CRYSTALLINE FORMS THEREOF 审中-公开
标题翻译： RALTEGRAVIR SALTS及其结晶形式
公开(公告)号：WO2011123754A1
公开(公告)日：2011-10-06
申请号：PCT/US2011/030892
申请日：2011-04-01
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , KWOKAL, Ana , HEDVATI, Lilach , BURSTEIN, Revital , YEORI, Adi , MOSHKOVITS-KAPTSAN, Rinat
发明人： KWOKAL, Ana , HEDVATI, Lilach , BURSTEIN, Revital , YEORI, Adi , MOSHKOVITS-KAPTSAN, Rinat
IPC分类号： C07D413/12
CPC分类号： C07D413/12
摘要： The present invention includes new salts of Raltegravir and crystalline forms thereof, pharmaceutical compositions containing the salts or crystalline forms, methods of using the salts or crystalline forms or the compositions to treat HIV infection or to prepare medicament for treating HIV infection, and a process for preparing Raltegravir potassium.
摘要翻译：本发明包括Raltegravir及其结晶形式的新盐，含有盐或结晶形式的药物组合物，使用盐或结晶形式的方法或用于治疗HIV感染的组合物或制备用于治疗HIV感染的药物的方法，制备Raltegravir钾。

8. 发明申请

WO2010039885A2 CRYSTALLINE FORMS OF DEXLANSOPRAZOLE 审中-公开
标题翻译：苯并噻唑的结晶形式
公开(公告)号：WO2010039885A2
公开(公告)日：2010-04-08
申请号：PCT/US2009/059103
申请日：2009-09-30
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , RENDELL, Jacob , MITTELMAN, Ariel , MOSHKOVITS-KAPTSAN, Rinat , FINE, Sergei , KWOKAL, Ana , KOLTAI, Tamas
发明人： RENDELL, Jacob , MITTELMAN, Ariel , MOSHKOVITS-KAPTSAN, Rinat , FINE, Sergei , KWOKAL, Ana , KOLTAI, Tamas
IPC分类号： C07D401/12 , A61K31/44
CPC分类号： C07D401/12
摘要： Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof.
摘要翻译：提供了右兰索拉唑的结晶形式，以及其制备方法。

9. 发明申请

WO2008137134A2 AMORPHOUS ELETRIPTAN HYDROBROMIDE AND PROCESS FOR PREPARING IT AND OTHER FORMS OF ELETRIPTAN HYDROBROMIDE 审中-公开
标题翻译：非索非那曲坦碱水解物及其制备及其他形式的盐酸氯替尼尔
公开(公告)号：WO2008137134A2
公开(公告)日：2008-11-13
申请号：PCT/US2008/005770
申请日：2008-05-01
申请人： PLUS CHEMICALS, B.V. , TEVA PHARMACEUTICALS USA, INC. , MENDELOVICI, Marioara , LANCRY, Eli , MOSHKOVITS-KAPTSAN, Rinat
发明人： MENDELOVICI, Marioara , LANCRY, Eli , MOSHKOVITS-KAPTSAN, Rinat
IPC分类号： C07D403/06 , A61K31/404 , A61P25/06
CPC分类号： C07D403/06
摘要： The invention encompasses amorphous eletriptan hydrobromide, processes for preparing it and pharmaceutical compositions of it. The invention also relates to processes for preparing other forms of eletriptan hydrobromide such as Form α and Form β.
摘要翻译：本发明包括无定形的伊马替丁氢溴酸盐，其制备方法和药物组合物。本发明还涉及制备其它形式的依托曲坦氢溴酸盐的方法，例如Form a和Formβ。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式